קיוביצין - Cubicin

קיוביצין - Cubicin
התוויות	Cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae subsp. equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms. Daptomycin is not indicated for the treatment of pneumonia. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be adjusted as needed based upon test results. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubicin and other antibacterial drugs Cubicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibiliry information are available they should be considered in selecting or modifying antibacterial therapy. In the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Staphylococcus aureus bloodstream infections (bacteremia) influding those with right-sided endocarditis caused by methicillin - susceptible and methicillin - resistant strains

דרך מתן

מינונים

התוויות נגד

תופעות לוואי

פרמקוקינטיקה

פרמקודינמיקה

תגובות בין-תרופתיות

שימוש בהריון

מאמרים

מידע ברשת

RxList‏ (UK)

WebMD

MedlinePlus

קיוביצין - Cubicin


מרכיב פעיל	DAPTOMYCIN
קבוצה פרמקולוגית (ATC)	"OTHER ANTIBACTERIALS"
שם התרופה	"קיוביצין®" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	לא כלול
התוויות	Cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae subsp. equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms. Daptomycin is not indicated for the treatment of pneumonia. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be adjusted as needed based upon test results. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubicin and other antibacterial drugs Cubicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibiliry information are available they should be considered in selecting or modifying antibacterial therapy. In the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Staphylococcus aureus bloodstream infections (bacteremia) influding those with right-sided endocarditis caused by methicillin - susceptible and methicillin - resistant strains
שם יצרן	CUBIST PHARMACEUTICALS INC, USA
שם בעל הרישום	MEDISON PHARMA LTD